ANDA 40162, held by Ivax Sub Teva Pharms. Prochlorperazine Maleate.
As of Nov 16, 2026, ANDA 40162 (Prochlorperazine Maleate), held by Ivax Sub Teva Pharms, was first approved by FDA on Jan 20, 1998, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 20, 1998 | Original application | Approved |
| Prochlorperazine MaleateEQ 5MG BASE · tablet;oral | Prochlorperazine Maleate | Discontinued |
| Prochlorperazine MaleateEQ 10MG BASE · tablet;oral | Prochlorperazine Maleate | Discontinued |
| Jul 29, 2002 | Supplement 11Manufacturing | Approved | None posted |
| Sep 12, 2001 | Supplement 9Manufacturing | Approved | None posted |
| Nov 13, 2000 | Supplement 8Manufacturing | Approved | None posted |
| Nov 13, 2000 | Supplement 7Manufacturing | Approved | None posted |
| Oct 17, 2000 | Supplement 6Labeling | Approved | None posted |
| May 1, 2000 | Supplement 5Manufacturing | Approved | None posted |
| May 1, 2000 | Supplement 4Manufacturing | Approved | None posted |
| Jan 28, 2000 | Supplement 3Manufacturing | Approved | None posted |
| Nov 23, 1999 | Supplement 2Manufacturing | Approved | None posted |
| Dec 9, 1998 | Supplement 1Manufacturing | Approved | None posted |
| Jan 20, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters